Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.

Oral oncology - 1 May 2014

Tomihara Kei, Fuse Hiroki, Heshiki Wataru, Takei Rie, Zhang Bin, Arai Naoya, Nakamori Kenji, Noguchi Makoto

Abstract excerpt

OBJECTIVES: Gemcitabine (GEM) is a pyrimidine nucleoside analogue that is a new chemotherapeutic agent used for treating various cancers. Because accumulating evidence indicates that GEM may activate host immune responses, its potential as an immune modulator in cancer chemotherapy has generated considerable interest. MATERIALS AND METHODS: In the present study, we investigated the antitumor effects of GEM using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Lymphocyte Culture Test, Mixed

Share to Mice, Inbred C3H

Share to Mouth Neoplasms

Share to T-Lymphocytes

Source

Identifiers

PMID: 24582211
DOI: 10.1016/j.oraloncology.2014.01.013

Genes

GEM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.PMID 24582211Read ↗

A novel mouse model for checkpoint inhibitor-induced adverse events.Semantic proximity Read ↗

Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma.Semantic proximity Read ↗

Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and FunctionsSemantic proximity Read ↗

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulationSemantic proximity Read ↗

Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.Semantic proximity Read ↗

Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner.Semantic proximity Read ↗

Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells.Semantic proximity Read ↗

CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer.Semantic proximity Read ↗

Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate ImmunitySemantic proximity Read ↗

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer modelSemantic proximity Read ↗

Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells.Semantic proximity Read ↗

Preclinical Studies of Granulysin-Based Anti-Tn Immunotoxins as A New Antitumoral TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.